{
    "clinical_study": {
        "@rank": "131133", 
        "arm_group": [
            {
                "arm_group_label": "Traumeel", 
                "arm_group_type": "Experimental", 
                "description": "Traumeel tablets by mouth the total amount for 72 hours will be 26 tablets"
            }, 
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "The Placebo tablets (300 mg lactose monohydrate and 1,5 mg magnesium stearate) by mouth the total amount for 72 hours will be 26 tablets"
            }
        ], 
        "brief_summary": {
            "textblock": "To investigate and compare the effects of Traumeel\u00aeS tablets versus placebo on recovery and\n      inflammatory immune response over a period of 72 hours after a second bout of strenuous\n      concentric exercise on bicycle (exercise #2)."
        }, 
        "brief_title": "Effects of Traumeel\u00aeS Tablets on Recovery and Inflammatory Immune Response After Repeated Bouts of Exercise", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Exercise-induced Muscle Soreness", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Sex: male\n\n          -  Age \u2265 18 and \u2264 40 years\n\n          -  BMI \u2265 18.5 and < 27,5 kg/m2 (WHO standard for normal range BMI)\n\n          -  Maximum relative oxygen uptake (VO2max) < 53 ml/kg x min\n\n          -  General state of good health\n\n          -  Non-smoker\n\n          -  Medically approved unrestricted participation in sports as shown by diagnostic\n             performance test conducted on treadmill no longer than 3 months prior to study entry\n\n          -  Willingness to provide signed informed consent\n\n        Exclusion Criteria:\n\n          -  Weekly training volume \u2265 6 hours\n\n          -  Use of dietary supplements (incl. high-dosed vitamins and minerals)\n\n          -  Chronic immune deficiency\n\n          -  Current infection\n\n          -  Heart and/or circulation disorders\n\n          -  Abnormal findings on exercise ECG\n\n          -  Musculoskeletal disorders\n\n          -  Any current clinical condition that requires systemic treatment or might have an\n             impact on study objectives\n\n          -  Hypersensitivity to botanicals of the Compositae family (e.g. Echinacea)\n\n          -  Lactose intolerance\n\n          -  Illicit drug or alcohol abuse\n\n          -  Participation in another clinical trial within 4 weeks prior to study entry"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "40 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "95", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "August 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01921777", 
            "org_study_id": "TEIR-3", 
            "secondary_id": "2009-010899-17"
        }, 
        "intervention": [
            {
                "arm_group_label": "Traumeel", 
                "description": "oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning", 
                "intervention_name": "Traumeel", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Placebo", 
                "description": "oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Muscle", 
            "exercise", 
            "soreness", 
            "Damage", 
            "Traumeel", 
            "homeopathy"
        ], 
        "lastchanged_date": "January 20, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Giessen", 
                    "country": "Germany", 
                    "zip": "35394"
                }, 
                "name": "Department of Sports Medicine, Institute of Sports Science, University of Giessen"
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "overall_official": {
            "affiliation": "Department of Sports Medicine, Institute of Sports Science, University of Giessen", 
            "last_name": "Frank C. Mooren, Prof. Dr.", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours of Interleukin-1 receptor antagonist (IL-1ra)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours of Interleukin 6 (IL-6)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01921777"
        }, 
        "responsible_party": {
            "investigator_affiliation": "University of Giessen", 
            "investigator_full_name": "Prof. Dr. med. Frank Christoph Mooren", 
            "investigator_title": "Prof. Dr. med. Frank Christoph Mooren", 
            "responsible_party_type": "Sponsor-Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours of other immunomodulators (35 lab parameters)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours of immune status and activation markers (7 lab parameters)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours of muscle damage markers (2 lab parameters)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours of maximum isometric strength (separately for thigh flexors and extensors)", 
                "safety_issue": "No", 
                "time_frame": "72 hours"
            }, 
            {
                "measure": "Changes in post-exercise two baseline levels up to 72-hours Short Form McGill Questionnaire total scores and separate VAS pain ratings", 
                "safety_issue": "No", 
                "time_frame": "72-hours"
            }
        ], 
        "source": "University of Giessen", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Biologische Heilmittel Heel GmbH", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "University of Giessen", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Prof. Dr. med. Frank Christoph Mooren", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "January 2010", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}